Scholar Rock upsizes public offering to $85M gross, prices 12.4M shares at $6.85

Scholar Rock Holding Corp

Gross proceeds of $85M from 12,408,760 shares at $6.85; underwriter option fully exercised for additional 1,861,314 shares.
Net proceeds after full exercise estimated at ~$92.5M; offering closed October 16, 2023.
Proceeds to advance apitegromab and clinical/preclinical pipeline, plus working capital.
J.P. Morgan and Piper Sandler lead underwriting; BMO and Wedbush as co-managers.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Scholar Rock Holding Corp entered into Underwriting Agreement with J.P. Morgan Securities LLC, and Piper Sandler & Co., as representatives of the several underwriters named therein (the “Underwriters”) valued at $6.85 per share (effective 2023-10-11).

Action: entry
Agreement: underwriting
Counterparty: J.P. Morgan Securities LLC, and Piper Sandler & Co., as representatives of the several underwriters named therein (the “Underwriters”)
Value: $6.85 per share
Effective: 2023-10-11

Exact text from the filing

On October 11, 2023, Scholar Rock Holding Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, and Piper Sandler & Co., as representatives of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale of an aggregate of 12,408,760 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) to the Underwriters (the “Offering”).

View on SEC.gov

Browse all material agreements →

Scholar Rock Holding Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-108849

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.